BioCryst Pharmaceuticals, Inc.

Healthcare

NASDAQ:BCRX · NASDAQ Global Select

Market Cap $1.72B Beta 0.56 P/E (TTM) -4.6

$8.70 +2.35%

+$0.20 today

52W Low $6.00High $10.47

Vol 2.39M · Avg 5.21M

EPS (TTM)-$1.89

Biotechnology

Filings

Ground the analysis in primary documents

Pair price history with recent company filings so you can connect market moves to the actual disclosures behind the business.

Price History

Dividend-adjusted closing price

Events

Change

-16.10%

Period High

$10.37

Period Low

$6.24

Latest

$8.70

SEC Filings

Recent regulatory filings

No filings found.

Competitors

Peer companies in the same sector

Health

Spyre Therapeutics, Inc.

NASDAQ:SYRE

$4.88B

Pharvaris N.V.

NASDAQ:PHVS

$2.15B

Trevi Therapeutics, Inc.

NASDAQ:TRVI

$2.02B

Stoke Therapeutics, Inc.

NASDAQ:STOK

$1.86B

Zymeworks Inc.

NASDAQ:ZYME

$1.68B

Ardelyx, Inc.

NASDAQ:ARDX

$1.41B

Intellia Therapeutics, Inc.

NASDAQ:NTLA

$1.36B

Maze Therapeutics, Inc.

NASDAQ:MAZE

$1.33B

Wave Life Sciences Ltd.

NASDAQ:WVE

$1.13B

Upstream Bio, Inc.

UPB

$331.96M

What is the latest BCRX filing?

The latest filing shown is 8-K dated Jun 12, 2026.

How many recent filings does BCRX have?

Intrinsic Alpha currently shows 20 recent filings for BCRX.

Explore More

Continue the stock analysis

Jump to another research area for this company.

OverviewStart with valuation, alerts, peers, and the full company snapshot.DCFAdjust assumptions and compare intrinsic value against the market price.FinancialsReview income statement, balance sheet, and cash flow trends.HealthCheck liquidity, leverage, and balance sheet strength.GrowthCompare historical growth, cash generation, targets, and peers.DividendsInspect dividend history, payout durability, and shareholder returns.ManagementReview leadership context, insider activity, and capital efficiency.